To main content

SINTEF Industry Biotechnology and Nanomedicine

RESEARCH, TECHNOLOGY AND INNOVATION

Biotechnology and nanomedicine are key enabling technologies for various sectors of society and multiple industries. The technology is used in development of pharmaceuticals, vaccines, biomaterials, enzymes, food, feed, chemicals and energy. SINTEF Industry has a strong operation in the fields of microbial molecular biology, bioprocess- and medical technology, biopolymers/polymers, biopharmaceuticals and nanomedicine, and is operating a state-of-the-art research infrastructure including advanced mass spectrometry.

Trond Erling Ellingsen
Research Director
930 59 489

Expertise

Top

3D bioprinting, and additive manufacturing (AM) for health/medicine applications in general

Biopharmaceuticals, medical technology and nanomedicine

Downstream processing – Product isolation, purification and characterization

Environmental Biotechnology and Microbiology

Food and Feed Microbiology and Biochemistry

Functional metagenomics and enzyme technology

High throughput screening

Industrial Biotechnology - Efficient strains and processes

Marine Biotechnology and bioprospecting

Mass spectrometry and separation science in Biotechnology

Nanomedicine

Polymer particles and capsules

Systems and synthetic biology

Laboratories

Top

High throughput screening facility, Trondheim

The robotic screening facility at SINTEF are optimized for high throughput analytical and cultivation work and enables us to process of thousands of samples or cultures per day.

Molecular biology laboratory

We have state of the art equipment for molecular biology, including an Illumina MiSeq sequencer, droplet digital PCR (ddPCR), Agilent Bioanalyzer, CHEF Mapper XA pulse field gel electrophoresis system and a Bluepippin cassette-based gel electrophoresis system for DNA and protein separation, in addition to ÄKTA FPLC equipment for protein purification. Our co-workers have several years of experience and master most topics and protocols related to genetic modification of bacteria.

Fermentation laboratory at SINTEF

SINTEF has a nationally leading research laboratory for development of microbial and cell based production processes. The laboratory has robotic equipment for miniaturized cultivation, large capacity incubators for shake flasks, laboratory fermentors (1-3 L) equipped for extensive process control and monitoring, and a pilot plant with two fermenters (50 and 300 L) for scale-up studies and small productions.

Mass spectrometry - Advanced research-based analyses

We perform research-based mass spectrometric (MS) and high-throughput (HTS) analyses for SINTEF, academia and industry.
All laboratories

Projects

Top

Mucoprotect – A novel generic system for targeted delivery of oral vaccines

10 August 2018

Vaccines are by far the most important tool in preventing disease in Norwegian aquaculture. Without the systematic use of efficient vaccines industrialisied fish farming would be an impossibility. Despite this, 53 million salmon were lost in Norway in 2017 due to illness and injury, also related to salmon lice treatment. In the project we will develop novel, clever vaccines based on nanoparticles, tailored for oral vaccination.

SIP GUT: Development of tools for gut microbiota research

25 September 2020

The gut microbiota are the microorganisms that live in the gastrointestinal tract. They play a fundamental role in health and disease of the host. Detailed understanding of gut microbiota–host interactions is therefore of great importance as this may be used to find new treatments to various diseases and increase the well-being of humans and animals.

TrippelTarg - Triple Targeting of Biodegradable Nanoparticles for Treatment of Cancer

25 September 2020

SINTEF want to further develop a targeted treatment strategy that has shown promising effects in animals with patient-derived tumors. The strategy is based on the use of nanoparticles developed by SINTEF containing a cytostatic drug.
All projects

News

Top

How safe are the new Covid vaccines?

14 January 2021

The new vaccines designed to combat the Covid-19 virus have been developed in record time, causing some people to be sceptical of taking them. Should we be worried about side effects? Norwegian SciTech News has been talking to two research scientists about this issue.

Getting the body to make its own cancer drugs

20 May 2020

Imagine that we could instruct our bodies to make the drugs they need themselves. The gene technology that makes this possible is called mRNA therapy, which may become a major tool in the treatment of multiple diseases. Norwegian researchers are currently helping to develop a drug of this kind to treat the most aggressive form of breast cancer.

EU-OPENSCREEN ERIC: EU initiative supports research on future medical chemistry

14 June 2019

Use EU-OPENSCREEN ERIC’s newly funded EU-OPENSCREEN-DRIVE project to advance your research now.
All news